Aditi Banerjee

1. Drive differentiation, maturation, and cell banking of human iPSC-derived cardiomyocytes (hiPSC-CMs) for reproducible modeling of cardiac physiology, injury, and repair mechanisms. 2. Optimize cardiac differentiation and maturation protocols to improve sarcomeric organization, electrophysiological fidelity, and metabolic responsiveness in advanced in vitro cardiac models. 3. Lead translational studies on non-necrotic and immune-mediated troponin release, including macrophage-induced cardiomyocyte injury models, to dissect cellular stress and biomarker dynamics. 4. Develop and analytically validate immunoassays for cardiac biomarkers (e.g., troponin, DNA damage markers), supporting mechanistic insight and clinical translation. 5. Perform high-resolution immunohistochemistry (IHC), cryo-/paraffin tissue sectioning, and high-content imaging (HCI) to characterize cardiac and vascular tissue morphology and injury pathways. 6. Integrate multi-omics platforms—including flow cytometry, LC-MS-based metabolomics, and quantitative RNA assays—to investigate Takotsubo cardiomyopathy, ischemic heart disease, and associated metabolic remodeling. 7. Engineer complex co-culture systems combining iPSC-derived cardiomyocytes and immune cells (macrophages, T cells) to explore cellular crosstalk, inflammation, and cardiotoxicity. 8. Advance predictive in vitro cardiovascular safety platforms, linking molecular and metabolic signatures with functional readouts to enable mechanism-driven biomarker discovery and translational toxicology.

1. Drive differentiation and maturation of human iPSC-derived cardiomyocytes (hiPSC-CMs) to model cardiac physiology and stress response pathways. 2. Optimize cardiac differentiation protocols to enhance structural and electrophysiological fidelity in vitro models of cardiac injury and disease. 3. Lead translational studies investigating non-necrotic troponin release mechanisms, integrating biochemical, molecular, and imaging-based assays. 4. Develop and validate immunoassays for cardiac biomarkers (e.g., troponin, DNA damage markers) supporting mechanistic and clinical translation. 5. Perform advanced immunohistochemistry (IHC), cryo-/paraffin tissue sectioning, and high-content imaging (HCI) for cardiac and vascular tissue analysis. 6. Collaborate on preclinical projects exploring Takotsubo cardiomyopathy and ischemic heart disease, employing multi-omics workflows including flow cytometry, LC-MS-based metabolomics, and RNA quantification assays. 7. Design and refine complex co-culture systems (cardiomyocytes–immune cell models) to investigate cardiac injury, stress signaling, and metabolic adaptation. 8. Advance in vitro cardiovascular safety platforms, linking molecular signatures to functional endpoints for predictive toxicology and biomarker discovery.

1. Investigate chemotherapeutic drug responses in glioblastoma cell lines and primary PBMCs, focusing on DNA damage signaling and immune modulation. 2. Execute multi-color flow cytometry panels for T cell activation, proliferation, and cytotoxicity profiling, integrating high-dimensional immune phenotyping. 3. Perform cytokine and chemokine profiling using multiplex immunoassays to assess tumor–immune cell crosstalk and inflammatory signatures. 4. Identify and validate biomarkers associated with DNA damage response (DDR) and immunomodulatory mechanisms, supporting precision oncology strategies. 5. Develop and optimize in vitro functional assays for T cell–tumor interactions, checkpoint modulation, and therapeutic efficacy assessment. 6. Integrate molecular and functional endpoints to advance understanding of immune-mediated effects of anticancer therapeutics and inform personalized treatment design.

Cardiovascular Target Safety, CPSS Evaluated receptor protein expression and inhibitor toxicity in human cardiac primary cells and hiPSC-derived cardiomyocytes. Conducted mitochondrial metabolic profiling using Seahorse analysis and qPCR to assess cardiomyocyte growth and ATP flux. Performed advanced imaging analysis with fluorescence staining and software tools like MetaExpress and Columbus03. Established workflows for robotic instrumentation and designed experiments to enhance team productivity.

Developed and optimized in vitro diagnostic (IVD) assays for diabetes detection (HbA1c), ensuring compliance with ISO 13485 and GMP standards. Led assay verification and validation, collaborated with QA and regulatory teams, and contributed to SOP development. Applied data analysis and quality management expertise to enhance assay performance and reliability in a regulated environment.